Body Mass Index and Smoking

Written by Scott Peeples, BS Biomedical Sciences | ExomeDNA Founder Reviewed by ExomeDNA Editorial Process

Body mass index measured within smoking populations captures a metabolic phenotype shaped by the intersection of genetic predisposition and the pharmacological effects of nicotine. Nicotine suppresses appetite and elevates resting metabolic rate through nicotinic acetylcholine receptor activation, creating a unique biological environment in which BMI-associated genetic variants may operate through different or amplified mechanisms compared to non-smokers. Variants near CHRNB4 and ADAMTS7 emerge as significant signals in this trait, pointing toward nicotinic receptor subunit biology and extracellular matrix remodeling in metabolic tissues as key determinants of BMI within the smoker-specific context.

What is Body Mass Index in Smokers?

Body mass index (BMI) analyzed within smoking populations reveals a genetic architecture shaped by the overlay of baseline metabolic biology with chronic nicotinic receptor activation. Because nicotine's weight effects are mediated through specific receptor subtypes, genetic variation in those receptor subunits creates detectable BMI variance within the smoker population that is invisible in non-smoker cohorts.

Genome-wide association studies of smoker-stratified BMI identify variants whose effects are either amplified or revealed by the nicotinic pharmacological context. These signals illuminate the interface between genetic predisposition and a specific environmental exposure—tobacco—making smoker-BMI genetics a distinct and biologically informative phenotype category.

Research base: Moderate

The genetics behind BMI in Smokers

CHRNB4: nicotinic acetylcholine receptor β4 subunit

CHRNB4 encodes the beta-4 subunit of heteromeric nicotinic acetylcholine receptors (nAChRs). Nicotinic receptors are ligand-gated ion channels that respond to acetylcholine (endogenous) and nicotine (exogenous). The β4 subunit assembles with α3 subunits to form α3β4 nicotinic receptors—the predominant subtype in autonomic ganglia and in brain regions including the medial habenula and interpeduncular nucleus.

Nicotine's appetite-suppressing effects are mediated partly through hypothalamic nicotinic receptor activation, which modulates the activity of appetite-regulating neurons expressing pro-opiomelanocortin (POMC) and agouti-related peptide (AgRP). Variants in CHRNB4 that alter β4 subunit expression or receptor assembly efficiency modulate how sensitively smokers' nicotinic receptor systems respond to nicotine, affecting the magnitude of nicotine-driven appetite suppression.

The biological logic is coherent: in a smoker population, individuals with more responsive nicotinic receptor systems (shaped partly by CHRNB4 variants) experience greater nicotine-induced appetite suppression, while those with lower receptor responsiveness benefit less from nicotine's weight-suppressive effects. This creates detectable BMI variance within the smoking population—variance that would not be visible in non-smokers who are not activating these pathways pharmacologically.

CHRNB4 is also expressed in the adrenal medulla, where nicotinic receptor activation stimulates catecholamine release. Catecholamines (epinephrine, norepinephrine) increase resting metabolic rate and lipolysis—an additional mechanism through which CHRNB4 variation could influence BMI in the context of chronic nicotine exposure.

ADAMTS7: extracellular matrix remodeling in metabolic tissues

ADAMTS7 encodes a disintegrin and metalloproteinase with thrombospondin motifs 7, a secreted zinc metalloproteinase that cleaves extracellular matrix (ECM) components including cartilage oligomeric matrix protein (COMP) and aggrecan. ADAMTS metalloproteinases regulate ECM turnover in connective tissues, and ECM remodeling is increasingly recognized as a critical component of adipose tissue expansion and contraction.

Adipose tissue expansion requires coordinated ECM remodeling to accommodate growing adipocytes and supporting vasculature. ADAMTS7-mediated ECM turnover in peri-adipocyte connective tissue may influence the mechanical and signaling microenvironment of expanding adipose depots. In the context of smokers—whose adipose tissue is chronically exposed to oxidative stress and inflammatory signals from tobacco combustion products—the efficiency of ECM remodeling could modulate how adipose depots respond to nicotine-mediated lipolytic signals.

Nicotinic receptor genetics and weight The CHRNB4 locus is one of the few BMI-associated genomic regions with a direct mechanistic link to the pharmacological mechanism of nicotine action. The α3β4 nicotinic receptor subtype in which CHRNB4 operates is expressed in brain regions governing autonomic function, reward, and appetite—making CHRNB4 a biologically compelling candidate for individual variation in nicotine's weight-regulatory effects across the smoker population.

Additional authorized genes

ETV5 encodes ETS variant transcription factor 5, expressed in adipose tissue where it regulates lipid metabolism and adipocyte differentiation; ETV5 variants appear in adult BMI and fat distribution GWAS. FHIT encodes fragile histidine triad diadenosine triphosphatase, involved in purine metabolism; its appearance in BMI genetics may reflect roles in cellular energy sensing. DGKG (diacylglycerol kinase gamma) regulates diacylglycerol levels in signaling cascades important in adipocyte and neuronal biology. CCDC39 encodes a coiled-coil domain protein involved in ciliary axoneme assembly with emerging evidence for metabolic roles. BDNF appears in this gene set as well, reflecting its broad role across BMI GWAS strata including smokers, though the primary biological angle for this trait is CHRNB4-driven nicotinic receptor biology.

What the research says

GWAS analyses of BMI stratified by smoking status (PMID 28443625, a large-scale BMI GWAS; PMID 35793639, a subsequent analysis) identify the CHRNB4 and ADAMTS7 loci as contributors to BMI variance specifically within smoking populations. Stratification by smoking status is methodologically important: it partitions the genetic architecture of BMI by the pharmacological context, revealing signals attenuated or absent in non-smoker strata.

The ADAMTS7 signal in BMI genetics is of particular interest given that ADAMTS7 is simultaneously a well-replicated coronary artery disease GWAS signal as a regulator of arterial ECM. The convergence of cardiovascular and metabolic GWAS signals at ADAMTS7 may reflect shared biology in vascular and metabolic ECM remodeling—especially relevant in smokers, whose vascular biology is additionally perturbed by tobacco-derived reactive oxygen species and inflammatory mediators.

Two independent evidence sources PMIDs 28443625 and 35793639 provide independent GWAS evidence for the smoker-BMI genetic architecture, conducted in different cohorts and analytical frameworks. Replication across independent datasets strengthens confidence in identified loci even within the more restricted analytical strata of smoker-only populations.

How BMI in Smokers affects you

Within a smoking population, BMI reflects an interaction between baseline metabolic genetics and the pharmacological context of nicotinic receptor activation:

Genetic sensitivity to nicotinic appetite suppression: CHRNB4 variants modulate how efficiently α3β4 nicotinic receptor systems respond to nicotine's appetite-suppressive and metabolic-rate-elevating signals. Greater receptor responsiveness translates to more nicotine-mediated appetite control; lower responsiveness means less—and this variance is detectable as BMI differences within the smoker population.

Adipose ECM biology under oxidative stress: ADAMTS7-mediated ECM remodeling affects how adipose tissue expands and contracts under metabolic pressure. In smokers, adipose biology operates under chronic oxidative and inflammatory load from tobacco, making ECM remodeling efficiency a more consequential determinant of fat depot dynamics than in non-smokers.

Shared and unique genetic architecture: The BMI genetic architecture in smokers overlaps with but is not identical to that in non-smokers. Loci like BDNF appear in both strata; loci like CHRNB4 are amplified or specific to the smoker context because they operate through nicotinic receptor biology that tobacco exposure activates.

The ExomeDNA score for this trait reflects aggregate variant effects across GWAS-identified loci in this smoker-stratified dataset. A higher score associates with higher BMI within the smoker population—not relative to non-smokers, but within the BMI distribution of individuals who smoke.

Working with your BMI in Smokers profile

Understanding nicotinic receptor sensitivity: If CHRNB4 variants indicate lower α3β4 receptor responsiveness, the appetite-suppressive pathway operating through nicotinic signaling may be less efficient. This has implications for understanding current BMI patterns and for cessation planning—since weight gain during smoking cessation is partly mediated by withdrawal of nicotinic appetite suppression.

Cessation and weight management: Nicotine replacement therapies that maintain some degree of nicotinic receptor activation during cessation may be more weight-neutral for individuals with stronger CHRNB4-mediated receptor sensitivity, while those with weaker nicotinic responsiveness may experience less cessation-related weight gain due to the smaller delta in nicotinic appetite suppression. A healthcare provider can help match cessation strategy to individual biology.

Adipose tissue support: Supporting healthy ECM remodeling in adipose tissue—the ADAMTS7 biology—aligns with anti-inflammatory dietary patterns, resistance exercise (which signals ECM remodeling in muscle and surrounding connective tissue), and adequate glycine, proline, and vitamin C for collagen-supporting nutrition. These interventions are broadly supported for smokers, whose ECM remodeling is additionally stressed by tobacco-derived reactive oxygen species.

Post-cessation dietary strategy: Weight gain during cessation is well-documented and partly genetic. Maintaining protein adequacy, consistent meal timing, and structured food environments during the cessation window can support weight stability as nicotinic appetite suppression withdraws. Aerobic exercise during cessation also upregulates BDNF in hypothalamic appetite circuits, providing a partial substitute for nicotinic appetite regulation.

Related traits and genes

• BMI in non-smokers (overlapping loci including BDNF; distinct signal at CHRNB4 which is smoker-context-specific)
• Nicotine dependence (CHRNB4 and adjacent CHRNA3 are among the most-replicated nicotine dependence GWAS signals)
• Coronary artery disease (ADAMTS7 is a well-replicated CAD GWAS signal via arterial ECM biology)
• Fat distribution (ETV5 and ADAMTS7 in waist-to-hip ratio and visceral adiposity research)
• Lung cancer susceptibility (the 15q25 CHRNB4/CHRNA3/CHRNA5 cluster is a major lung cancer GWAS locus)

Frequently asked questions

Q: Why does a nicotinic receptor gene like CHRNB4 appear in a BMI study of smokers? A: Nicotine suppresses appetite partly through nicotinic acetylcholine receptor activation in hypothalamic and autonomic circuits. CHRNB4 encodes a receptor subunit that shapes how sensitively these circuits respond to nicotine. Within a smoker population, genetic differences in CHRNB4-mediated receptor responsiveness create detectable variance in how much appetite suppression individuals experience from comparable nicotine exposure—accumulating into BMI differences over years.

Q: Does this mean smokers with this score have a genetic reason for why smoking affects their weight differently? A: Partly, yes. CHRNB4 variants contribute to individual differences in nicotinic receptor sensitivity, which is one mechanistic reason why two people who smoke similar amounts may have different weight trajectories. This is a statistical contribution to a complex trait, not a one-gene determination.

Q: How does ADAMTS7 connect to weight in smokers specifically? A: ADAMTS7 is a metalloproteinase that remodels extracellular matrix in metabolic and vascular tissues. In smokers, adipose tissue ECM operates under elevated oxidative and inflammatory stress from tobacco combustion products. Variants in ADAMTS7 that alter ECM remodeling efficiency may have amplified effects on adipose tissue dynamics in the smoker context compared to non-smokers whose ECM is under less oxidative pressure.

Q: Is this score relevant after quitting smoking? A: Smoking cessation substantially changes the metabolic context in which these genetic signals operate. Post-cessation, the CHRNB4-mediated nicotinic appetite suppression pathway withdraws, and BMI may increase as a consequence. The non-smoker BMI score becomes more applicable over time after cessation. The ADAMTS7 biology (ECM remodeling) remains relevant post-cessation, though the oxidative stress context of active smoking diminishes.

Q: Does the CHRNB4/CHRNA3/CHRNA5 cluster also relate to nicotine dependence? A: Yes. The 15q25 chromosomal region harboring CHRNB4, CHRNA3, and CHRNA5 is one of the most robustly replicated loci in nicotine dependence and lung cancer GWAS. Variants in this cluster affect nicotinic receptor subunit composition and expression in ways that influence both dependence vulnerability and the metabolic effects of nicotine—explaining why the same genomic region produces a BMI signal in smoker-stratified analyses.

Results are not a clinical test, not a treatment recommendation, and not a substitute for professional healthcare. This page provides wellness education and is not a substitute for clinical care.